Automatic search for statistics

Komorebi | 木漏れ日
“Sunlight filtering through leaves” [1]

Can’t stand hunting through a cytometry dashboard to find the exact filters to be able to do statistically valid comparisons? Neither can we. 

Out of that frustration, we’ve just released “Automatic search for valid statistics”, now on your app.teiko.bio dashboard.

The Challenge: Clinical datasets have missing values. It’s a reality of running clinical trials: patients miss a dose, something doesn’t get measured, etc. The show must still go on. 

However, finding exactly which sets of samples you can even do a statistical comparison on is still too tough. 

For example, your favorite graphing software stumbles on a deceptively simple dataset like this:

TimeResponder
Baseline27
On-Treatment17

To make valid paired statistical comparisons for responders, you have to hunt for all 17 subjects that have both a Baseline and On-treatment samples, set the filter and run the test. This is both error-prone, time-consuming and difficult, because you would have to find the 10 samples (i.e. 27 Baseline – 17 on-treatment) that don’t have a corresponding pair.

The Solution: Our new automatic search tool scans our statistical test database for “tallies” – complete records based on a specified endpoint and cell types. We then auto-apply the right filters so you can see valid statistical comparisons.

In the case above, the result of the automatic filtering, you would see only the 17 baseline samples that had a corresponding non-responder pair. Compare this to trying to find all 10 samples that don’t have a corresponding pair. Huge time saver.

Available now at app.teiko.bio, this feature simplifies high-dimensional cytometry analysis for clinical trial teams. Check out the demo at app.teiko.bio.

If there are no statistics showing on the dashboard, this button becomes enabled, allowing you to do this automatic search.

[1] Literally “sunlight filtering through leaves,” this term encapsulates the natural, transient interplay of light and shadow, evoking a sense of wonder and subtle beauty.

Teiko releases Yokozuna: Absolute Cell Counts, Unified “Immune Changes” Tab, Smarter Memory, Now on Your Dashboard

Yokozuna | 横綱 | Champion Sumo Wrestler

We’re excited to announce an update to our CLIA-validated cytometry service, enhancing your ability to analyze immune cell dynamics with greater precision and clarity. This update is now available for customers using our TokuKit fixed whole blood samples.

Key Updates

  1. Expanded Data Visualization: Absolute Cell Counts, Relative Cell Frequencies, and Event Counts
    Our dashboard now includes three measurements: absolute cell counts (measured in cells per uL), relative cell frequencies (measured in percentages, i.e. % of Leukocytes), and event counts recorded by the instrument.
    • You can now:
      • View absolute cell counts for all gated populations and functional subsets on app.teiko.bio.
      • Access boxplots, stacked bars, and other visualizations showing absolute cell counts, to assess treatment response, track immune recovery, and correlate cell numbers with clinical outcomes more accurately.
      • Identify statistically significant differences in absolute cell counts between groups or over time, offering deeper insights into your drug’s mechanism of action.
    • This feature is currently exclusive to customers using Teiko’s TokuKit on fixed whole blood samples. To access these enhancements, ensure your samples are prepared using TokuKit, and securely integrate your CRO’s absolute cell count data with our dashboard. Stay tuned for future development of this feature on PBMCs.
    • Why even bother to look at absolute cell counts?
      • Absolute cell counts provide precise quantification of immune cell numbers per microliter of blood, addressing the limitations of relying solely on relative frequencies. This update helps you detect subtle changes in immune populations, monitor therapeutic efficacy, develop robust biomarkers, and identify safety concerns with greater confidence.

2. Unified Immune Changes Tab: We’ve simplified our Dashboard by consolidating the “Immune Changes Over Time” and “Immune Differences” tabs into a single, intuitive “Immune Changes” tab. Under one tab, you can compare changes in immune cell populations over time and across groups (e.g., responders vs. non-responders), streamlining workflow and data interpretation. When you click an endpoint that has time, you’ll see a drop-down showing specific time-series toggles, like “Connect Timepoints by Subject.” When you click an endpoint that’s not time-based, these will disappear.

3. Smarter Memory: Now, if you select a set of cells, i.e. “Switched B Memory” in Population Frequencies, and switch tabs to Population Counts, we’ll remember the settings you picked. This saves you time so you don’t have to hunt and click through menus to get your desired results.

Teiko to present original research at inaugural AACR IO conference

We’re excited to present our latest research at the first-ever American Association for Cancer Research in Immuno-oncology (AACR IO), highlighting findings that challenge traditional assumptions about fresh blood processing in cytometry. We’ll be at the conference from February 23rd to 26th, sharing insights from our newest study.

🔬 Introducing the “Fresh-Hour” ⏰🩸
Our research looks to see how delays in processing, measured in hours after blood draw (or “Fresh-Hours”), reflective of processing whole blood live within a 72-hour window of collection like in a clinical trial, impact cytometry results.

Here’s what we discovered:

Blood processed within 5 hours (“Fresh-5”) maintained stable immune cell population frequencies.
By 72 hours (“Fresh-72”), there was a 48% percent drop in immune cell counts from t = 0, highlighting the need for new approaches to profile blood by cytometry to ensure the results reflect the true biology of patients.

Come visit us at AACR IO and reach out to set up a meeting—we’d love to connect!

Title: Are fresh specimens really all that fresh? An examination of cell loss over time in high-parameter cytometry.
Presentation Time: Poster Session A, February 24, 2025, 1:45-4:45 p.m. PT
Presenting Author: @Carly Lancaster
Poster Number: A072

TokuFocus: Announcing “focused” panels for spectral flow and mass cytometry

TokuFocus: Announcing “focused” panels for spectral flow and mass cytometry.

Codename: Daiki | 大喜 | Champion Sumo Wrestler

Teiko’s cytometry services allow you to measure 146 – 840 of populations, a 6-17X increase compared to conventional 13-marker flow cytometry panels.

However, many immunotherapy developers are worried about the cost and need of measuring the extra populations. Drug developers sometimes say, “I just need to measure TBNK by flow first. If the drug shows activity in the TBNK populations, then, and only then, would I care about the other populations.”

The TokuFocus is designed with this drug developer in mind. You can start with a TBNK panel subset, covering 10 markers at $1,000 per specimen. You can then upgrade to the full panel at any time within a year for an additional $900 per specimen. In short, you get the option to see the rest of the immune tree when you want (and only when you want).

What problem TokuFocus solves:

  • Drug developers who need a quick analysis of TBNK populations but who don’t want to lose the option of detailed immune population analysis. These developers want to focus on TBNK populations first and analyze the rest of the immune tree after achieving successful readings.

How it works:

  • Each sample will be run on a full, 25-marker or 41-marker panel.
  • For $1,000 per specimen, customers can access the data for a basic 10-marker TBNK panel. 
  • With the software-based upgrade, customers can unlock access to the data for the full panel for $900 per specimen, without having to run additional samples. 
  • Required minimum specimens by cohort
    • Mass Cytometry: 20 specimen
    • Spectral Flow Cytometry: 50 specimen

What do I get after I upgrade?

  • Gated Data
  • FCS and GatingML Files
  • Dashboard: Immune Cell Composition, Box and Time Series Plots
  • 2 Consulting Hours

Key Features: 

With the 10-marker panel, customers can access features included in our core analysis tier. This includes data tables, sample and gating QC, and manually gated statistical analysis. Raw data files, like FCS and GatingML are only available after unlocking the remaining channels. These features will be available on Teiko’s dashboard, at app.teiko.bio. 

Within a year, customers can upgrade to unlock the data for the full panel. After upgrading, the analyzed data will be available within the dashboard, assuming a 50 specimen order.

FAQ:

  • Can I do this on a custom panel?
    • Not yet. This is built for our off-the-shelf panel.
  • Can I pick the subset?
    • Not yet. Here are the markers included in our basic TBNK panels:
SpectralMass Cytometry
PBMC (Viability, FSC x SSC)MarkerWhole Blood (fixed)PBMC (viability)MarkerWhole Blood (fixed)
CD4CD4 T cellCD4CD4CD4 T cellCD4
CD8CD8 T cellCD8CD8CD8 T cellCD8
CD45LeukocyteCD45CD45LeukocyteCD45
Neutrophil CleanupCD66bCD66bNeutrophil CleanupCD66b
CD3T cellCD3CD3T cellCD3
CD19B cellCD19CD19B cellCD19
CD56NK CellCD56CD56NK CellCD56
CD16NK, MonocyteCD16CD16NK, MonocyteCD16
CD14MonocyteCD14CD14MonocyteCD14
CD11cConventional DCCD11cCD11cConventional DCCD11c
  • What if I want to run multiple cohorts?
    • We can support this, however spectral flow requires 50 specimens per cohort, and mass cytometry requires 20 specimens per cohort.
  • Is the full gating tree available?
    • Yes, you will get the full gating tree on the dashboard. You’ll see the unavailable populations greyed out.
  • Can I cherry pick which samples to upgrade? That is, if I send you 50 samples, can I upgrade 30?
    • Not yet, you cannot select which samples to upgrade. That is, the upgrades are “all or nothing.”
  • How do you do unsupervised analysis?
    • We don’t do unsupervised analysis on the focused panel. If you’re interested in that, you have to unlock the remainder of the panel. Once you unlock the panel, you have the option to upgrade for an additional fee.

Teiko releases absolute cell counts for CLIA-validated cytometry service

We’re introducing a new add-on to our cytometry service that provides absolute cell counts in addition to relative frequencies. This gives you precise quantification of immune cell numbers, helping you better assess treatment impact, track immune recovery, and correlate cell counts with clinical outcomes for more informed decision-making.

How it works

  • From each patient, two specimens are collected. One will go to your regular CRO for your absolute cell count, and one will go to Teiko for cytometry. Teiko will integrate the data.
  • For the first specimen, send according to your CRO’s instructions to get the initial absolute cell count and provide us the following information per specimen:
    • Required
      • Specimen ID
      • White Blood Cell (WBC) / ul
    • Optional
      • Granulocytes / ul
      • Lymphocytes / ul
      • Monocytes / ul
  • The other sample is prepared using Teiko’s proprietary TokuKit, designed to preserve and optimize the sample for multi-parameter cytometry.
  • Securely update the data from the CRO’s lab to Teiko.
  • Teiko will update your results to show the number of cells per uL.

Pain Point:

Within high-dimensional cytometry, there is a challenge to directly provide the cell concentration or absolute count of cells in a sample. Yet, these measurements are a precise and reliable quantification for developers to accurately assess the mechanisms of their drug.

Relying solely on relative cell count, frequency of an immune cell population relative to a parent population, can provide a misleading picture of true mechanism of action for a drug.

Incorrect interpretation with Relative Frequencies alone

Relative Frequencies (Proportion of Non-Gran)
TimeCAR-TMonocytesNon-Gran
Baseline8%20%100%
Day 77%20%100%
InterpretationDecreaseStableUnchanged

With this chart, a reader would think this drug is posting a decrease in CAR-T Cells, while monocytes remain stable.

With absolute cell counts, the picture is clearer.

Correct insight with Absolute Cell Count

Absolute Cell Counts (cells/μL of blood)
TimeCAR-TMonocytesNon-Gran
Baseline50012006000
Day 750015007500
InterpretationStableIncreaseIncrease

Here, you can see that CAR-T Cells remain stable, there’s an increase in monocytes, and an increase in total non-Granulocytes.

Key Features:

Customers can view absolute cell counts for all gated populations and functional subsets on app.teiko.bio, in addition to relative frequencies that are already reported for all projects.

Under the “Immune Boxplot” tab, view a boxplot showing the range, standard deviation, and median absolute cell count for each gated population.

Under “Immune Differences,” you can now view boxplots showing the absolute cell count for each population and functional subset. Compare absolute cell counts for each population for any given group (responders vs nonresponders, across dose levels, or other groups of interest) and identify statistically significant differences between groups.

Under “Immune Changes Over Time,” generate plots that show the changes in absolute cell count per subject over time, and compare between timepoints to see if the changes are statistically significant.

Data tables will also include a column next to each population and functional subset frequency that also shows its absolute cell count.

The addition of absolute cell counts allows you to gain a more complete and precise understanding of immune system dynamics by providing the number of cells per microliter present in each gate in your samples, rather than just their relative proportions and cell counts. This data is crucial for evaluating the true biological impact of your drug or treatment, as it enables you to:

  • Detect changes in immune cell populations, even when relative frequencies or cell counts might not fully capture the magnitude of these changes.
  • Monitor immune recovery or depletion in response to treatment, providing a clearer picture of therapeutic efficacy.
  • Develop more robust biomarkers for treatment response by correlating absolute cell counts with clinical outcomes like patient recovery, progression, or survival.
  • Identify potential safety concerns, such as excessive immune cell depletion or unwanted immune activation, by tracking absolute counts across critical immune subsets.

Announcing the availability of 25 marker spectral flow cytometry assay on fixed whole blood

Release: Hakuhō | 白鵬 | Champion Sumo Wrestler

We are thrilled to unveil our latest innovation for drug developers: a spectral flow cytometry panel using fixed whole blood collected with our TokuKit. This cutting-edge service allows you to analyze 146 immune populations with precision in our CLIA-registered lab.

Precision AssayInter-RunIntra-Run
Benchmark≤25%≤20%
Median % CV
Phenotypic Cell Populations
4.56%3.38%
% of population passing95.5%98.2%
Median % CV
Functional Marker Subsets
7.28%5.50%
% of population passing90.9%93.5%
This table showcases the precision of the assay, demonstrating high reproducibility with low median % CV values for both inter-run and intra-run measurements of phenotypic cell populations and functional marker subsets.

Stability Assay1 month12 months (accelerated)24 months (accelerated)
Benchmark≤25%≤25%≤25%
Median % change
Phenotypic Cell Populations
6.51%5.20%7.74%
% of population passing90.4%87.7%80.7%
Median % change
Functional Marker Subsets
8.36%8.03%12.94%
% of population passing80.4%79.5%72.1%
This table illustrates the stability of the assay, showing that the median % change for phenotypic cell populations and functional marker subsets remains within acceptable limits even after accelerated aging for 12 and 24 months.

Pricing

Starting at $1,250 per specimen: teiko.bio/pricing.

Why Choose Spectral Flow Cytometry?

Spectral flow cytometry takes immune monitoring to the next level:

  • Rapid speeds: Receive publication-quality results on ~100 samples in as little as ~6 weeks.
  • Read More, Analyze Deeper: Profile 146 immune cell populations and functional marker subsets with unparalleled resolution, covering T cells, B cells, NK cells, monocytes, dendritic cells, and their subsets, in each whole blood sample. You can theoretically measure up to 280 populations on this panel, allowing for detailed pharmacodynamic assessment. 
  • Better Data Quality: Spectral unmixing minimizes signal spillover, ensuring accurate detection of co-expressed markers.
  • Easier data comparability: If you know conventional flow, you can interpret spectral flow data easily.

Why Choose TokuKit for Fixed Whole Blood?

  • Access more clinical sites: No centrifugation or fresh blood processing required—collect, fix, and stabilize at the clinical site in under 20 minutes with our TokuKit.
  • Unmatched Stability: Samples are stable for up to 24 months at -80°C in our accelerated stability studies, enabling true longitudinal studies and batch normalization.
  • Overcomes the limitations of banked PBMCs: PBMC lose granulocytes, have higher variability in viability, cost $200-$300 per sample, and require specialized equipment and training.
  • Proven Performance: Achieves a 0.97+ correlation between live and fixed whole blood population frequencies by spectral flow cytometry.

Our service is ideal for:

  • Global, multi-site clinical trials that need standardized sample handling.
  • Longitudinal immune monitoring for pharmacodynamic studies.
  • Reducing variability and enhancing statistical confidence in your results.

We’re solving the three biggest problems in cytometry on clinical trials: getting a blood sample, measuring hundreds of populations, and making sense of it all.

Contact us today to learn how our fixed whole blood spectral flow panel can transform your studies. For orders and inquiries, visit teiko.bio/contact.

Enhanced Population Selection for Immune Composition Analysis

Release: Yozakura | 夜桜 | Night Cherry Blossom

Feature overview:

We’ve introduced a significant update to our immune composition visualization tool, offering users unprecedented flexibility in analyzing immune cytometry data. Previously, analyses were locked to a fixed top-level population, specifically,, non-granulocytes and total leukocytes, limiting the scope of exploration across immune subsets.

What’s new?

  • Dynamic Top-Level Population Selection: A new drop-down menu enables users to select different top-level populations, such as T cells, B cells, or monocytes or other cell subsets within the immune hierarchy. This applies to both gated and unsupervised analyses.
  • Relative fraction and cell counts: Visualize cell subsets as proportions of any selected top-level population. For instance, when focusing on monocytes, breakdowns into classical, non-classical, and intermediate monocyte subsets are displayed as fractions of total monocytes.

Why this is important:

  • Before: Users could only view cell types as fractions of total non-granulocytes or leukocytes, limiting comparisons across distinct populations.
  • Now: By selecting “Monocytes” as the top-level population, for example, researchers can analyze monocyte subsets (e.g., classical, non-classical, intermediate) as fractions of total monocytes, for more specific and detailed insights. For unsupervised analyses on whole blood, the top-level gates can be set to non-granulocytes or granulocytes.

Improved Visualization:

With non-granulocytes selected, users can visualize the immune tree comprehensively, including all subsets under this branch.

By switching to a specific cell population, like monocytes, the view narrows to highlight specific monocyte subpopulations, providing detailed insights into the particular cell lineage.

Update your workflows to take full advantage of this new flexibility!

Fall 2024 Feature Releases 🍂

Normalization Baseline Selection Feature For Data Export

We’ve added a new feature in the data export tab, enabling you to select a normalization baseline for your data. Now, you can choose any time point as the baseline, and the data will be normalized accordingly. The default option is set to “no normalization,” allowing for complete flexibility based on your analysis needs.

Enhanced Navigation with New Collapsible Filter

We’ve upgraded our filtering interface with a new collapsible design. This accordion-style filter allows for easier navigation and quicker access to the metadata you need, streamlining the process of selecting filters and viewing data.

The previous layout required extensive scrolling to reach different filter options. With the collapsible filter, all options are now neatly organized and accessible, enabling you to focus on analysis without distractions.

Append: add new samples to your web app as the samples get processed

Customers who send us samples in rolling cohorts can see their samples updated as new samples come in. Imagine you have a 250 specimen trial. 100 specimens arrive in Cohort 1, and 150 specimens arrive in Cohort 2.

Previously, the addition of new samples led to a short period of downtime for the user’s web app as the new samples were added to the project. Now, samples are added to the web app without any downtime, and all statistics are recomputed for all samples. This update provides a more seamless experience for the customer.

“No samples left behind”: Missing a baseline sample, no sweat!

Previously, if a sample was missing in a certain group comparison, that group comparison would not yield statistical results. For example, assume you have a set of five patients.

If you want to compare B cells across two on-treatment timepoints (i.e. C1D2 and C1D15) normalized to the baseline, but one subject is missing the baseline sample, previously our statistical testing implementation would skip the comparison due to the incomplete data.

Let’s see this in action. If Patient two in the table below were missing a baseline sample, we wouldn’t be able to calculate statistical results. Now, by dynamically constructing the statistical test to remove the one patient with no baseline sample, we are able to calculate all statistical tests for the remaining four samples.

Patient #BaselineC1D2C1D15C2D1C2D15
1
2
3
4
5
Patient 2, missing a patient baseline sample

Now, say a subject is missing any timepoint (as in the table below). And assume the goal is to calculate paired statistics. Previously, if you tried comparing the means of these two groups at two different timepoints, no statistics would be shown. Our algorithm was strict and simply did not perform the comparison. Now, we filter out the subject with the missing sample and show statistics for the remaining patients.

Patient #C1D2C1D15
1
2
3
4
5
Patient 2, missing a second timepoint

Obsidian selects Teiko for high-dimensional immunophenotyping for OBX-115

Teiko and Obsidian Therapeutics are excited to announce our partnership for high-dimensional immunophenotyping of patients enrolled in the ongoing OBX-115 phase 1 / 2 clinical trial. Teiko’s CLIA-validated 25-marker spectral flow cytometry panel will allow Obsidian to profile 298 immune cell subsets and states in each patient’s peripheral blood sample. The panel covers T cell, NK cell, B cell, and myeloid subsets along with 5 functional markers to evaluate maturation, exhaustion, and activation across these subsets. Obsidian will use Teiko’s service to analyze and describe peripheral blood immune compartments in patients participating in their phase 1 / 2 clinical trial.

“We selected Teiko for spectral flow immunophenotyping because of the strong data they have already generated for us in preclinical activities, and we are excited to continue to expand our partnership to explore the immune impacts of OBX-115 across the entire immune system,” Giri Ramsingh, Vice President, Clinical Sciences, Obsidian Therapeutics. “We especially appreciate the rigorous validation that Teiko’s panels have gone through and the easy-to-use data analysis tools that have allowed us to visualize our findings.”

Teiko to present two posters at the 2024 SITC annual meeting

Teiko is excited to announce that two posters have been accepted for presentation at the 2024 Society for Immunotherapy of Cancer (SITC) annual meeting in Houston from November 8 – 10th. 

Teiko will present its work on optimizing fixed whole blood samples for mass cytometry, highlighting the development and validation of the TokuKit, a two-step collection kit that stabilizes whole blood for long-term storage at -80°C for up to 24 months. The poster will show inter- and intra-run validation for a 41+ marker pan-immunophenotyping panel and performance comparisons to fresh blood, supporting the use of the TokuKit in clinical trials for biomarker research and immune monitoring.

In addition, Teiko will also highlight its research on addressing the challenge of processing fresh blood for flow cytometry in clinical trials by optimizing the TokuKit fixation method for high-dimensional immune profiling using a 20+-marker spectral flow cytometry panel, which shows comparable (r=0.975) results to freshly processed samples.

Poster Presentation Details:

Abstract Title: It’s about time: Rapid on-site fixation of whole blood samples prior to high-dimensional flow cytometric analysis

Abstract Number: 57

Presenter: Kristina Magee, MD-PhD, Associate Director Lab Operations

Poster Presentation Date: Friday, Nov. 8 from 12:15 – 1:45PM, 5:30PM – 7:00PM

Read the poster here.

Watch the presentation here.

Abstract Title: It’s on-site: eliminating site-to-site variability with whole blood collection kits using 40+ marker TokuProfile mass cytometry assay

Abstract Number: 58

Presenter: Justin Jarrell, PhD, VP Business Development

Poster Presentation Date: Saturday, Nov. 9 from 12:15PM – 1:45PM, 7:00PM – 8:30PM

Read the poster here.

Watch the presentation here.